|Brand name(s), other common name(s)||Reblozyl®|
|Drug type||Erythroid maturation agent|
|How the drug is given||Injection, for subcutaneous use|
Indications and Usage
Luspatercept-aamt is FDA approved for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
Limitations of Use: Reblozyl is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Side effects needing medical attention
The most common adverse reactions were fatigue, headache, musculoskeletal pain, pain in a joint (arthralgia), dizziness/vertigo, nausea, diarrhea, cough, abdominal pain, difficulty breathing (dyspnea), and hypersensitivity.